OBJECTIVES:  Allergic rhinoconjunctivitis (ARC) is a common disorder, with a prevalence of 17-29% in European adults. Asthma affects around 6% of the French population with considerable Medical Resource Utilization (MRU). Our study aimed to detail MRU and related direct cost in Perennial Allergic Rhinitis (PAR), with or without concomitant allergic asthma (AA) in France. METHODS:  Using French Electronic Health Records (EHRs), we identified in 2010 two cohorts of patients, based on General Practitioners’ diagnoses, prescribing and clinical data. The first cohort included patients with PAR but no AA, while the second cohort included patients with PAR and concomitant AA. For each patient, the medical record was linked to corresponding claims data with reimbursed MRU and costs between 2011 and 2013. In each cohort, sub-groups analyses were performed according to severity of rhinitis and level of asthma control. RESULTS:  The mean total annual cost for a patient with PAR and no AA was 247€ in 2013. This varied from 202€ to 298€ depending on rhinitis severity. Medical consultations made up almost 50% of these costs, while allergy drug made up 10%. For patients with PAR and concomitant AA, the mean annual cost varied between 403€ and 550€, depending on the level of asthma control. Asthma drugs accounted for 20% and medical consultations for 35% of the costs. CONCLUSIONS:  This innovative study linking diagnoses from EHRs to claims data (MRU) was one of the first of its kind to be conducted in France, certainly in allergy. It collected valid data on PAR management, with or without concomitant AA, and on related costs. There was a clear relationship between MRU or associated costs, and severity of PAR and control of AA. Improved disease control for patients with PAR and AA would decrease the burden of disease.